I G Petrochemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 22, 2025, 4:00 am

Competitors of I G Petrochemicals Ltd

All Competitor Stocks of I G Petrochemicals Ltd

Quarterly Result

Last Updated: August 20, 2025, 9:20 am

Below is a detailed analysis of the quarterly data for I G Petrochemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 470.05 Cr.. The value appears to be declining and may need further review. It has decreased from 480.08 Cr. (Mar 2025) to 470.05 Cr., marking a decrease of 10.03 Cr..
• For Expenses, as of Jun 2025, the value is 467.85 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 431.23 Cr. (Mar 2025) to 467.85 Cr., marking an increase of 36.62 Cr..
• For Operating Profit, as of Jun 2025, the value is 2.20 Cr.. The value appears to be declining and may need further review. It has decreased from 48.85 Cr. (Mar 2025) to 2.20 Cr., marking a decrease of 46.65 Cr..
• For OPM %, as of Jun 2025, the value is 0.47%. The value appears to be declining and may need further review. It has decreased from 10.18% (Mar 2025) to 0.47%, marking a decrease of 9.71%.
• For Other Income, as of Jun 2025, the value is 10.85 Cr.. The value appears strong and on an upward trend. It has increased from 4.96 Cr. (Mar 2025) to 10.85 Cr., marking an increase of 5.89 Cr..
• For Interest, as of Jun 2025, the value is 8.23 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.71 Cr. (Mar 2025) to 8.23 Cr., marking a decrease of 2.48 Cr..
• For Depreciation, as of Jun 2025, the value is 15.63 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.36 Cr. (Mar 2025) to 15.63 Cr., marking a decrease of 0.73 Cr..
• For Profit before tax, as of Jun 2025, the value is -10.81 Cr.. The value appears to be declining and may need further review. It has decreased from 26.74 Cr. (Mar 2025) to -10.81 Cr., marking a decrease of 37.55 Cr..
• For Tax %, as of Jun 2025, the value is -24.05%. The value appears to be improving (decreasing) as expected. It has decreased from 21.58% (Mar 2025) to -24.05%, marking a decrease of 45.63%.
• For Net Profit, as of Jun 2025, the value is -8.21 Cr.. The value appears to be declining and may need further review. It has decreased from 20.98 Cr. (Mar 2025) to -8.21 Cr., marking a decrease of 29.19 Cr..
• For EPS in Rs, as of Jun 2025, the value is -2.67. The value appears to be declining and may need further review. It has decreased from 6.81 (Mar 2025) to -2.67, marking a decrease of 9.48.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:10 am

Growth

Last Updated: September 5, 2025, 6:50 am

Balance Sheet

Last Updated: June 16, 2025, 11:59 am

Below is a detailed analysis of the balance sheet data for I G Petrochemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 31.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,297.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,209.00 Cr. (Mar 2024) to 1,297.00 Cr., marking an increase of 88.00 Cr..
• For Borrowings, as of Mar 2025, the value is 238.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 337.00 Cr. (Mar 2024) to 238.00 Cr., marking a decrease of 99.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 602.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 517.00 Cr. (Mar 2024) to 602.00 Cr., marking an increase of 85.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,168.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,094.00 Cr. (Mar 2024) to 2,168.00 Cr., marking an increase of 74.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,016.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,030.00 Cr. (Mar 2024) to 1,016.00 Cr., marking a decrease of 14.00 Cr..
• For CWIP, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 38.00 Cr..
• For Investments, as of Mar 2025, the value is 242.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2024) to 242.00 Cr., marking a decrease of 10.00 Cr..
• For Other Assets, as of Mar 2025, the value is 868.00 Cr.. The value appears strong and on an upward trend. It has increased from 809.00 Cr. (Mar 2024) to 868.00 Cr., marking an increase of 59.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,168.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,094.00 Cr. (Mar 2024) to 2,168.00 Cr., marking an increase of 74.00 Cr..

Notably, the Reserves (1,297.00 Cr.) exceed the Borrowings (238.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for I G Petrochemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 35.29. This value is within the healthy range. It has increased from 12.83 (Mar 24) to 35.29, marking an increase of 22.46.
• For Diluted EPS (Rs.), as of Mar 25, the value is 35.29. This value is within the healthy range. It has increased from 12.83 (Mar 24) to 35.29, marking an increase of 22.46.
• For Cash EPS (Rs.), as of Mar 25, the value is 56.48. This value is within the healthy range. It has increased from 29.75 (Mar 24) to 56.48, marking an increase of 26.73.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 434.70. It has increased from 404.87 (Mar 24) to 434.70, marking an increase of 29.83.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 434.70. It has increased from 404.87 (Mar 24) to 434.70, marking an increase of 29.83.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 716.35. It has increased from 681.56 (Mar 24) to 716.35, marking an increase of 34.79.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 79.42. This value is within the healthy range. It has increased from 44.13 (Mar 24) to 79.42, marking an increase of 35.29.
• For PBIT / Share (Rs.), as of Mar 25, the value is 58.24. This value is within the healthy range. It has increased from 27.21 (Mar 24) to 58.24, marking an increase of 31.03.
• For PBT / Share (Rs.), as of Mar 25, the value is 45.64. This value is within the healthy range. It has increased from 17.34 (Mar 24) to 45.64, marking an increase of 28.30.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 35.29. This value is within the healthy range. It has increased from 12.83 (Mar 24) to 35.29, marking an increase of 22.46.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 35.29. This value is within the healthy range. It has increased from 12.83 (Mar 24) to 35.29, marking an increase of 22.46.
• For PBDIT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has increased from 6.47 (Mar 24) to 11.08, marking an increase of 4.61.
• For PBIT Margin (%), as of Mar 25, the value is 8.12. This value is below the healthy minimum of 10. It has increased from 3.99 (Mar 24) to 8.12, marking an increase of 4.13.
• For PBT Margin (%), as of Mar 25, the value is 6.37. This value is below the healthy minimum of 10. It has increased from 2.54 (Mar 24) to 6.37, marking an increase of 3.83.
• For Net Profit Margin (%), as of Mar 25, the value is 4.92. This value is below the healthy minimum of 5. It has increased from 1.88 (Mar 24) to 4.92, marking an increase of 3.04.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.92. This value is below the healthy minimum of 8. It has increased from 1.88 (Mar 24) to 4.92, marking an increase of 3.04.
• For Return on Networth / Equity (%), as of Mar 25, the value is 8.11. This value is below the healthy minimum of 15. It has increased from 3.16 (Mar 24) to 8.11, marking an increase of 4.95.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.13. This value is within the healthy range. It has increased from 5.31 (Mar 24) to 11.13, marking an increase of 5.82.
• For Return On Assets (%), as of Mar 25, the value is 4.91. This value is below the healthy minimum of 5. It has increased from 1.85 (Mar 24) to 4.91, marking an increase of 3.06.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 0.2. It has decreased from 0.18 (Mar 24) to 0.12, marking a decrease of 0.06.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has decreased from 0.29 (Mar 24) to 0.19, marking a decrease of 0.10.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.02. There is no change compared to the previous period (Mar 24) which recorded 1.02.
• For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has decreased from 1.51 (Mar 24) to 1.46, marking a decrease of 0.05.
• For Quick Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1. It has decreased from 1.15 (Mar 24) to 0.96, marking a decrease of 0.19.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.94. This value exceeds the healthy maximum of 8. It has decreased from 11.51 (Mar 24) to 8.94, marking a decrease of 2.57.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 21.24. This value is within the healthy range. It has decreased from 77.93 (Mar 24) to 21.24, marking a decrease of 56.69.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.27. This value is below the healthy minimum of 20. It has decreased from 33.60 (Mar 24) to 13.27, marking a decrease of 20.33.
• For Earning Retention Ratio (%), as of Mar 25, the value is 78.76. This value exceeds the healthy maximum of 70. It has increased from 22.07 (Mar 24) to 78.76, marking an increase of 56.69.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 86.73. This value exceeds the healthy maximum of 70. It has increased from 66.40 (Mar 24) to 86.73, marking an increase of 20.33.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.30. This value is within the healthy range. It has increased from 4.47 (Mar 24) to 6.30, marking an increase of 1.83.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.80. This value is within the healthy range. It has increased from 2.30 (Mar 24) to 3.80, marking an increase of 1.50.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,390.98. It has decreased from 1,505.60 (Mar 24) to 1,390.98, marking a decrease of 114.62.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.63. This value is below the healthy minimum of 1. It has decreased from 0.71 (Mar 24) to 0.63, marking a decrease of 0.08.
• For EV / EBITDA (X), as of Mar 25, the value is 5.69. This value is within the healthy range. It has decreased from 11.08 (Mar 24) to 5.69, marking a decrease of 5.39.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 0.63 (Mar 24) to 0.59, marking a decrease of 0.04.
• For Retention Ratios (%), as of Mar 25, the value is 78.75. This value exceeds the healthy maximum of 70. It has increased from 22.06 (Mar 24) to 78.75, marking an increase of 56.69.
• For Price / BV (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.06 (Mar 24) to 0.97, marking a decrease of 0.09.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 0.63 (Mar 24) to 0.59, marking a decrease of 0.04.
• For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.08, marking an increase of 0.06.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness